Alnylam Pharmaceuticals, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersCambridge, MA
US patents433
SAM.gov UEIVV5NU81Q9VT1
CAGE code9H5L7
Incorporated inDE
LEI529900S3ZI14OWRJII50
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
433 US patents granted 2008–2025, 136 of them in the five years to SEP 2025.
Pharmaceuticals 341Biotechnology 76Organic fine chemistry 11Measurement 3Optics 2
- Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereofUS 12,416,006 · granted SEP 16, 2025
- Ketohexokinase (KHK) iRNA compositions and methods of use thereofUS 12,404,508 · granted SEP 2, 2025
- Extrahepatic deliveryUS 12,397,013 · granted AUG 26, 2025
- Coronavirus IRNA compositions and methods of use thereofUS 12,391,945 · granted AUG 19, 2025
- Modified double-stranded RNA agentsUS 12,385,044 · granted AUG 12, 2025
Newest 5 shown · Granted to Alnylam Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Alnylam Pharmaceuticals, INC. | Cambridge | MA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.